--- title: "Eli Lilly's Teriparatide is expected to become the strongest \"weight loss drug\" Institution: Sales expected to reach USD 27 billion by 2029" description: "Eli Lilly's Tirzepatide is expected to become the most powerful weight-loss drug, with projected sales of $27 billion by 2029. Tirzepatide has been approved by the US FDA and is available in US pharma" type: "news" locale: "en" url: "https://longbridge.com/en/news/104905444.md" published_at: "2023-12-25T06:21:06.000Z" --- # Eli Lilly's Teriparatide is expected to become the strongest "weight loss drug" Institution: Sales expected to reach USD 27 billion by 2029 > Eli Lilly's Tirzepatide is expected to become the most powerful weight-loss drug, with projected sales of $27 billion by 2029. Tirzepatide has been approved by the US FDA and is available in US pharmacies. It is considered more effective than Novo Nordisk AS's semaglutide and Victoza, especially for overweight or obese patients. Tirzepatide works by mimicking hormones to stimulate insulin release, increase satiety, and reduce appetite. This research is based on a large-scale analysis that found patients taking Tirzepatide were more likely to achieve successful weight loss compared to those taking semaglutide. Zhitong App has learned that Novo Nordisk's semaglutide (brand name Wegovy) has caused a storm in the weight loss industry in 2023, making it the most dazzling star product. However, Eli Lilly's tirzepatide has emerged as a potential challenger. Data and analytics company GlobalData believes that the strong clinical data on the weight loss efficacy of tirzepatide will surpass semaglutide and become the best-selling drug in the obesity and diabetes market, with sales expected to reach $27 billion by 2029. In November 2023, tirzepatide received approval from the U.S. Food and Drug Administration (FDA) for its indication in obesity (brand name Zepbound). In early December, Eli Lilly announced that its weight loss drug Zepbound had been launched in U.S. pharmacies and is suitable for severely obese adults. It is reported that the main ingredient of Zepbound is tirzepatide, which works by mimicking hormones to stimulate insulin release, increase satiety, and reduce appetite. Since 2022, Eli Lilly's tirzepatide has been marketed as Mounjaro for the treatment of type 2 diabetes. At the end of November, Truveta Research, a research institution in the medical and health field, released a large-scale analysis based on patient data from healthcare systems. The analysis found that for overweight or obese adults, Eli Lilly's Mounjaro, which contains tirzepatide, is more effective than Novo Nordisk's Ozempic, which contains semaglutide. The analysis compared nearly 18,000 overweight or obese patients who took Eli Lilly's tirzepatide drug Mounjaro and Novo Nordisk's semaglutide drug Ozempic from May last year to September this year. Among these patients, nearly 52% also had type 2 diabetes. The analysis found that those who took the former were more likely to achieve weight loss. If Mounjaro is taken, the likelihood of a patient losing 5% of their body weight is 1.8 times higher than if Ozempic is taken, the likelihood of losing 10% is six times higher, and the likelihood of losing 15% is three times higher. The results after a period of medication also showed that Mounjaro had better weight loss effects than Ozempic. After three months of taking Mounjaro, the median weight loss for patients was 5.9%, while for those taking Ozempic during the same period, the median weight loss was 3.6%. After six months of taking Mounjaro, the median weight loss for patients was 10.1%, while for those taking Ozempic, the weight loss was 5.9%. After one year of taking Mounjaro, the median weight loss for patients was 15.2%, while for those taking Ozempic, the weight loss was 7.9%. On behalf of Dolphin Research, I would like to express our gratitude for your continued support and interest in our work. We are thrilled to announce the release of our latest Analysis Report, which provides a comprehensive overview of the current market trends and developments in the industry. In this Earnings Report, we have analyzed the financial performance of various companies, including their MoM, YoY, and QoQ growth rates. We have also examined the impact of key factors such as market competition, consumer behavior, and regulatory changes on the overall performance of the industry. One of the highlights of this report is the in-depth analysis of Longbridge's recent achievements and future prospects. We have closely examined their strategic initiatives, product innovations, and market positioning, providing valuable insights for investors and industry professionals. Furthermore, we have also included a special feature on the latest developments in the technology sector. With the rapid advancement of artificial intelligence, blockchain, and other emerging technologies, we have witnessed significant changes in the competitive landscape. Our report sheds light on the opportunities and challenges that lie ahead for companies in this dynamic environment. We would like to extend our sincere thanks to our research team for their dedication and hard work in producing this comprehensive report. We hope that this report will serve as a valuable resource for your investment decisions and strategic planning. If you have any questions or would like to receive a copy of the report, please don't hesitate to contact us. Thank you once again for your support, and we look forward to continuing our partnership with you. Best regards, Dolphin Research ### Related Stocks - [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md) - [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Puzo Michael J 在诺和诺德公司 $NVO 拥有价值 32 万美元的股票持仓 | Puzo Michael J 在第三季度大幅减持了 Novo Nordisk A/S (NYSE:NVO) 的股份，减少幅度达到 86.9%，目前持有 5,775 股，价值 320,000 美元。其他机构投资者也调整了他们的持仓，True | [Link](https://longbridge.com/en/news/276447697.md) | | 诺和诺德公司董事会提议再次选举 Lars Rebien Sorensen 担任主席 | 诺和诺德公司董事会提议重新选举拉斯·瑞比恩·索伦森为董事长 | [Link](https://longbridge.com/en/news/276440991.md) | | 诺和诺德公司提议任命两名新的董事会成员 | 丹麦制药公司诺和诺德公司提议在 3 月 26 日于哥本哈根举行的年度股东大会上新增三名董事会成员。提议的成员包括海伦娜·萨克森、扬·范·德·温克尔和拉莫娜·塞奎拉。萨克森此前已宣布辞去 Sobi 的职务以加入诺和诺德。还提议重新选举董事长拉 | [Link](https://longbridge.com/en/news/276442777.md) | | 诺和诺德公司：将在 Ozempic 和 Wegovy 专利到期时准备好替代产品 - Berlingske | 丹麦制药公司诺和诺德计划在其药物 Ozempic 和 Wegovy 的专利于 2031 年在欧洲和 2032 年在美国到期时，准备好替代药物。研究负责人马丁·霍尔斯特·朗格表示，某些临床试验中的候选药物可能会在 2030 年前提交审批。有关 | [Link](https://longbridge.com/en/news/276314777.md) | | 诺和诺德公司获得欧洲委员会批准使用更高剂量的 Wegovy 注射剂 | 2026 年 2 月 17 日东部时间上午 9:25（MT Newswires）-- 诺和诺德公司（NVO）周二表示，欧洲委员会已批准 Wegovy 的 7.2 毫克每周一次的维持剂量，适用于肥胖成年人。诺和诺德公司表示，此次批准是基于欧洲 | [Link](https://longbridge.com/en/news/276138110.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.